Brain Tumor Diagnosis & Therapeutics Market by Therapeutic Modality (Chemotherapy, Immunotherapy, Radiation Therapy), Imaging Technology (Computed Tomography, Magnetic Resonance Imaging, Molecular Diagnostics), Tumor Type, Tumor Grade, Patient Age Group,
Description
The Brain Tumor Diagnosis & Therapeutics Market was valued at USD 1.78 billion in 2024 and is projected to grow to USD 1.95 billion in 2025, with a CAGR of 9.65%, reaching USD 3.73 billion by 2032.
An authoritative orientation to the changing clinical, technological, and strategic forces shaping contemporary brain tumor diagnosis and therapeutic decision making
The landscape of brain tumor diagnosis and therapeutics is evolving under the combined pressures of scientific innovation, regulatory scrutiny, and clinical necessity. Advances in molecular biology and imaging have reshaped how clinicians detect, classify, and treat intracranial neoplasms, while multidisciplinary care models are redefining patient pathways from initial presentation through long-term survivorship. Against this backdrop, stakeholders across industry, academia, and healthcare delivery are recalibrating priorities to accelerate translational research and improve patient outcomes.
Emerging diagnostic modalities and therapeutic platforms have converged to create new decision points for clinicians and payers alike. Precision diagnostics now inform individualized therapeutic choices, and targeted interventions are increasingly paired with companion imaging and molecular monitoring. These shifts demand integrated strategies that bridge early discovery, clinical validation, commercialization, and health system adoption. This introduction frames the critical themes that follow and highlights why cohesive, evidence-based planning is essential for organizations operating in this complex and rapidly changing field.
How precision diagnostics, theranostic integration, immuno-oncology advances, and AI-enabled imaging are jointly redefining the brain tumor care paradigm
The past decade has seen several transformative shifts that are now accelerating adoption curves and altering competitive dynamics within brain tumor care. First, precision medicine approaches have migrated from concept to clinical utility as genomic and transcriptomic profiling inform both diagnostic refinement and targeted therapy selection. This molecular granularity has reduced diagnostic ambiguity for many tumor subtypes and has enabled adaptive trial designs that can more rapidly demonstrate clinical benefit.
Second, theranostic integration-where diagnostic imaging and targeted therapeutics are developed in parallel-has reduced time-to-treatment for select patient cohorts and improved the granularity of response assessment. Third, immuno-oncology modalities such as CAR T-cell platforms and checkpoint inhibitors are moving from early-phase experimentation toward later-stage evaluation in defined glioma and metastatic central nervous system indications, creating a new therapeutic frontier that demands specialized delivery, monitoring, and safety protocols. Finally, digital health and AI-enhanced image analytics are enhancing diagnostic throughput and consistency, enabling remote second-opinion workflows and more efficient enrollment for precision trials. Together, these shifts are creating a more modular and collaborative innovation environment in which diagnostic clarity, therapeutic specificity, and operational scalability jointly determine success.
Assessing the practical repercussions and adaptive strategies spawned by 2025 tariff adjustments on supply chains, procurement, and equipment-dependent clinical operations
The introduction of new trade measures and tariff changes in 2025 created tangible operational headwinds for supply chain-sensitive segments of the brain tumor diagnosis and therapeutics ecosystem. Manufacturers of complex imaging equipment and specialized reagents experienced increased input costs and elongated procurement cycles, prompting some to re-evaluate regional sourcing strategies and inventory policies. These commercial responses have, in turn, influenced hospital capital planning and the timing of upgrades for high-cost modalities used in neuro-oncology workflows.
Clinicians and research institutions navigated these pressures by prioritizing maintenance and service optimization for installed equipment, accelerating the adoption of remote diagnostics that reduce cross-border logistics, and engaging in collaborative procurement arrangements. Regulators and payers also increased scrutiny on cost-effective adoption criteria, emphasizing outcomes-driven deployment. Although tariff-driven cost increases created near-term disruptions, they also catalyzed strategic adjustments that may yield longer-term resilience through diversified supplier relationships, localized manufacturing investments, and increased emphasis on consumable efficiency and assay consolidation.
A comprehensive, cross-cutting segmentation framework revealing where therapeutic classes, imaging modalities, care settings, tumor biology, and patient demographics converge to shape clinical strategy
A thorough segmentation lens is essential to understand where innovation and unmet need intersect across therapeutic modalities, imaging technologies, end users, tumor types, tumor grades, and patient age groups. Therapeutic modality segmentation spans chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy; within chemotherapy, alkylating agents, antimetabolites, and platinum compounds remain central to many regimens, while immunotherapy subdivides into CAR T-cell therapy, checkpoint inhibitors, and vaccine therapy, and targeted therapy includes antiangiogenic agents, mTOR inhibitors, and tyrosine kinase inhibitors. These modular distinctions influence clinical trial design, safety monitoring, and reimbursement pathways because each subcategory carries distinct efficacy benchmarks and toxicity profiles.
Imaging technology segmentation encompasses computed tomography, magnetic resonance imaging, molecular diagnostics, positron emission tomography, and ultrasound; within MRI, diffusion tensor imaging, functional MRI, and spectroscopy provide high-resolution functional and structural insights, while PET applications include amino acid tracers and FDG to enhance metabolic characterization. End users range from ambulatory surgical centers and diagnostic laboratories to hospitals and research institutes, and each setting imposes different throughput expectations, regulatory constraints, and capital intensity. Tumor type segmentation includes acoustic neuroma, glioma, meningioma, and pituitary tumor, and tumor grade divides into high grade and low grade, informing prognostic considerations and treatment aggressiveness. Patient age group segmentation differentiates adult, geriatric, and pediatric cohorts, each presenting unique biological behaviors, tolerability profiles, and supportive care needs. Integrating these intersecting segmentations enables more precise targeting of product development, clinical strategy, and value demonstration efforts across stakeholder groups.
Regional dynamics and strategic considerations that determine how technology adoption, regulatory pathways, and reimbursement approaches vary across major global markets
Regional dynamics significantly influence technology adoption, regulatory pathways, and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare networks and strong clinical research infrastructure support rapid enrollment into precision trials and early adoption of complex diagnostics, while reimbursement frameworks increasingly emphasize real-world evidence to justify advanced therapies. In contrast, Europe, Middle East & Africa present a heterogeneous landscape where regional regulatory harmonization and variations in public healthcare financing drive differentiated access timelines; policymakers in several jurisdictions prioritize cost-effectiveness and outcomes-based contracting to manage the adoption of high-cost interventions.
The Asia-Pacific region continues to expand both clinical research capacity and manufacturing footprint, with particular strength in scalable diagnostic platforms and localized reagent production that can reduce supply-chain exposure. Across these regions, differences in demographic trends, incidence patterns, and healthcare infrastructure require region-specific approaches to market entry, clinical validation, and commercialization. Recognizing these distinctions enables sponsors and vendors to design adaptive launch strategies, prioritize local partnerships, and align evidence generation with the expectations of regional payers and clinical communities.
Insights on how strategic alliances, platform innovators, and diagnostic and device manufacturers are shaping competitive trajectories in brain tumor care
Competitive activity in the brain tumor diagnosis and therapeutics domain spans multinational pharmaceutical and device majors, specialty biotech innovators, imaging system manufacturers, and diagnostics developers. Large pharmaceutical companies focus R&D resources on targeted agents and immuno-oncology combinations that can be integrated into standard-of-care regimens, leveraging global trial networks to validate biomarkers and companion diagnostics. At the same time, biotech firms are advancing platform technologies such as cellular therapies and novel delivery systems that address unmet safety and efficacy gaps in central nervous system oncology.
Equipment and imaging vendors continue to invest in software-driven enhancements and AI-enabled analytics that improve lesion detection and surgical planning, while diagnostic companies prioritize molecular assays and tracer development to refine tumor classification and monitor therapeutic response. Across the value chain, contract research organizations and specialized service providers play a critical role in enabling complex neuro-oncology trials, offering capabilities in biomarker assay development, central imaging read services, and advanced data analytics. Strategic partnerships, licensing deals, and co-development agreements remain prevalent as stakeholders seek to combine complementary strengths to advance therapeutic candidates and diagnostic innovations through regulatory and clinical pathways.
Actionable, high-impact strategic priorities that leaders should adopt to align diagnostic precision, therapeutic development, and evidence generation for sustained clinical adoption
Industry leaders should prioritize an integrated approach that aligns diagnostic clarity with therapeutic innovation and pragmatic commercialization pathways. First, invest in companion diagnostic development early in the therapeutic lifecycle to ensure that biomarker-defined patient populations are identified and validated for regulatory submissions. Second, build flexible manufacturing and supply chain arrangements to mitigate disruptions and optimize cost structures for imaging equipment, specialized reagents, and cell therapy inputs. Third, pursue collaborative clinical models that engage multi-stakeholder consortia-including academic centers, community hospitals, and patient advocacy groups-to accelerate enrollment and broaden the evidentiary base for diverse patient populations.
Additionally, companies should adopt data-centric strategies that leverage real-world evidence and AI-enabled analytics to demonstrate value to payers and clinicians. This entails designing post-market evidence generation plans that align with health system priorities and developing interfaces that integrate diagnostic outputs into electronic health records and clinical decision support tools. Finally, prioritize ethical deployment and patient-centric communication, especially for novel modalities with complex risk profiles, to foster clinician trust, support shared decision-making, and enhance long-term adoption.
A rigorous mixed-methods research approach combining literature synthesis, expert stakeholder engagement, and cross-validated primary insights to ensure actionable conclusions
The research methodology underpinning this report combines systematic literature synthesis, expert interviews, and cross-validated primary research to ensure a rigorous and current evidence base. Peer-reviewed publications, clinical trial registries, regulatory filings, and technical standards informed the technical and clinical background, while qualitative interviews with clinicians, industry executives, and payers provided contextual insights into operational challenges and adoption drivers. Secondary sources were triangulated with primary insights to validate assumptions and identify emerging inflection points.
Quantitative inputs were subjected to sensitivity analyses and scenario testing to assess the robustness of thematic conclusions, and a tiered evidence assessment framework guided the weighting of data sources. Special attention was paid to translational evidence linking diagnostic performance to clinical outcomes, the regulatory landscape for companion diagnostics and advanced therapies, and operational considerations for imaging and surgical deployment. This mixed-methods approach supports a pragmatic and actionable set of findings tailored to industry and clinical stakeholders.
Concluding synthesis highlighting the necessity of integrated diagnostics, translational investment, and stakeholder alignment to realize durable clinical benefits in brain tumor care
In sum, the trajectory of brain tumor diagnosis and therapeutics will be defined by the interplay of molecularly informed diagnostics, targeted and immunologic therapeutic strategies, and operational pathways that translate clinical promise into broad patient benefit. Cross-disciplinary collaboration remains essential to overcome persistent scientific and logistical barriers, particularly in the realms of drug delivery to the central nervous system, biomarker validation, and long-term safety monitoring for novel modalities. Equally important is the alignment of evidence generation with payer expectations to ensure that breakthroughs become accessible treatments rather than isolated clinical successes.
Moving forward, stakeholders that integrate robust diagnostic strategies, flexible commercial planning, and patient-centered communication will be best positioned to convert innovation into improved outcomes. Continued investment in translational research, coupled with pragmatic deployment strategies and regional sensitivity, will determine which technologies and therapies achieve durable clinical integration.
Please Note: PDF & Excel + Online Access - 1 Year
An authoritative orientation to the changing clinical, technological, and strategic forces shaping contemporary brain tumor diagnosis and therapeutic decision making
The landscape of brain tumor diagnosis and therapeutics is evolving under the combined pressures of scientific innovation, regulatory scrutiny, and clinical necessity. Advances in molecular biology and imaging have reshaped how clinicians detect, classify, and treat intracranial neoplasms, while multidisciplinary care models are redefining patient pathways from initial presentation through long-term survivorship. Against this backdrop, stakeholders across industry, academia, and healthcare delivery are recalibrating priorities to accelerate translational research and improve patient outcomes.
Emerging diagnostic modalities and therapeutic platforms have converged to create new decision points for clinicians and payers alike. Precision diagnostics now inform individualized therapeutic choices, and targeted interventions are increasingly paired with companion imaging and molecular monitoring. These shifts demand integrated strategies that bridge early discovery, clinical validation, commercialization, and health system adoption. This introduction frames the critical themes that follow and highlights why cohesive, evidence-based planning is essential for organizations operating in this complex and rapidly changing field.
How precision diagnostics, theranostic integration, immuno-oncology advances, and AI-enabled imaging are jointly redefining the brain tumor care paradigm
The past decade has seen several transformative shifts that are now accelerating adoption curves and altering competitive dynamics within brain tumor care. First, precision medicine approaches have migrated from concept to clinical utility as genomic and transcriptomic profiling inform both diagnostic refinement and targeted therapy selection. This molecular granularity has reduced diagnostic ambiguity for many tumor subtypes and has enabled adaptive trial designs that can more rapidly demonstrate clinical benefit.
Second, theranostic integration-where diagnostic imaging and targeted therapeutics are developed in parallel-has reduced time-to-treatment for select patient cohorts and improved the granularity of response assessment. Third, immuno-oncology modalities such as CAR T-cell platforms and checkpoint inhibitors are moving from early-phase experimentation toward later-stage evaluation in defined glioma and metastatic central nervous system indications, creating a new therapeutic frontier that demands specialized delivery, monitoring, and safety protocols. Finally, digital health and AI-enhanced image analytics are enhancing diagnostic throughput and consistency, enabling remote second-opinion workflows and more efficient enrollment for precision trials. Together, these shifts are creating a more modular and collaborative innovation environment in which diagnostic clarity, therapeutic specificity, and operational scalability jointly determine success.
Assessing the practical repercussions and adaptive strategies spawned by 2025 tariff adjustments on supply chains, procurement, and equipment-dependent clinical operations
The introduction of new trade measures and tariff changes in 2025 created tangible operational headwinds for supply chain-sensitive segments of the brain tumor diagnosis and therapeutics ecosystem. Manufacturers of complex imaging equipment and specialized reagents experienced increased input costs and elongated procurement cycles, prompting some to re-evaluate regional sourcing strategies and inventory policies. These commercial responses have, in turn, influenced hospital capital planning and the timing of upgrades for high-cost modalities used in neuro-oncology workflows.
Clinicians and research institutions navigated these pressures by prioritizing maintenance and service optimization for installed equipment, accelerating the adoption of remote diagnostics that reduce cross-border logistics, and engaging in collaborative procurement arrangements. Regulators and payers also increased scrutiny on cost-effective adoption criteria, emphasizing outcomes-driven deployment. Although tariff-driven cost increases created near-term disruptions, they also catalyzed strategic adjustments that may yield longer-term resilience through diversified supplier relationships, localized manufacturing investments, and increased emphasis on consumable efficiency and assay consolidation.
A comprehensive, cross-cutting segmentation framework revealing where therapeutic classes, imaging modalities, care settings, tumor biology, and patient demographics converge to shape clinical strategy
A thorough segmentation lens is essential to understand where innovation and unmet need intersect across therapeutic modalities, imaging technologies, end users, tumor types, tumor grades, and patient age groups. Therapeutic modality segmentation spans chemotherapy, immunotherapy, radiation therapy, surgery, and targeted therapy; within chemotherapy, alkylating agents, antimetabolites, and platinum compounds remain central to many regimens, while immunotherapy subdivides into CAR T-cell therapy, checkpoint inhibitors, and vaccine therapy, and targeted therapy includes antiangiogenic agents, mTOR inhibitors, and tyrosine kinase inhibitors. These modular distinctions influence clinical trial design, safety monitoring, and reimbursement pathways because each subcategory carries distinct efficacy benchmarks and toxicity profiles.
Imaging technology segmentation encompasses computed tomography, magnetic resonance imaging, molecular diagnostics, positron emission tomography, and ultrasound; within MRI, diffusion tensor imaging, functional MRI, and spectroscopy provide high-resolution functional and structural insights, while PET applications include amino acid tracers and FDG to enhance metabolic characterization. End users range from ambulatory surgical centers and diagnostic laboratories to hospitals and research institutes, and each setting imposes different throughput expectations, regulatory constraints, and capital intensity. Tumor type segmentation includes acoustic neuroma, glioma, meningioma, and pituitary tumor, and tumor grade divides into high grade and low grade, informing prognostic considerations and treatment aggressiveness. Patient age group segmentation differentiates adult, geriatric, and pediatric cohorts, each presenting unique biological behaviors, tolerability profiles, and supportive care needs. Integrating these intersecting segmentations enables more precise targeting of product development, clinical strategy, and value demonstration efforts across stakeholder groups.
Regional dynamics and strategic considerations that determine how technology adoption, regulatory pathways, and reimbursement approaches vary across major global markets
Regional dynamics significantly influence technology adoption, regulatory pathways, and commercial models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, integrated healthcare networks and strong clinical research infrastructure support rapid enrollment into precision trials and early adoption of complex diagnostics, while reimbursement frameworks increasingly emphasize real-world evidence to justify advanced therapies. In contrast, Europe, Middle East & Africa present a heterogeneous landscape where regional regulatory harmonization and variations in public healthcare financing drive differentiated access timelines; policymakers in several jurisdictions prioritize cost-effectiveness and outcomes-based contracting to manage the adoption of high-cost interventions.
The Asia-Pacific region continues to expand both clinical research capacity and manufacturing footprint, with particular strength in scalable diagnostic platforms and localized reagent production that can reduce supply-chain exposure. Across these regions, differences in demographic trends, incidence patterns, and healthcare infrastructure require region-specific approaches to market entry, clinical validation, and commercialization. Recognizing these distinctions enables sponsors and vendors to design adaptive launch strategies, prioritize local partnerships, and align evidence generation with the expectations of regional payers and clinical communities.
Insights on how strategic alliances, platform innovators, and diagnostic and device manufacturers are shaping competitive trajectories in brain tumor care
Competitive activity in the brain tumor diagnosis and therapeutics domain spans multinational pharmaceutical and device majors, specialty biotech innovators, imaging system manufacturers, and diagnostics developers. Large pharmaceutical companies focus R&D resources on targeted agents and immuno-oncology combinations that can be integrated into standard-of-care regimens, leveraging global trial networks to validate biomarkers and companion diagnostics. At the same time, biotech firms are advancing platform technologies such as cellular therapies and novel delivery systems that address unmet safety and efficacy gaps in central nervous system oncology.
Equipment and imaging vendors continue to invest in software-driven enhancements and AI-enabled analytics that improve lesion detection and surgical planning, while diagnostic companies prioritize molecular assays and tracer development to refine tumor classification and monitor therapeutic response. Across the value chain, contract research organizations and specialized service providers play a critical role in enabling complex neuro-oncology trials, offering capabilities in biomarker assay development, central imaging read services, and advanced data analytics. Strategic partnerships, licensing deals, and co-development agreements remain prevalent as stakeholders seek to combine complementary strengths to advance therapeutic candidates and diagnostic innovations through regulatory and clinical pathways.
Actionable, high-impact strategic priorities that leaders should adopt to align diagnostic precision, therapeutic development, and evidence generation for sustained clinical adoption
Industry leaders should prioritize an integrated approach that aligns diagnostic clarity with therapeutic innovation and pragmatic commercialization pathways. First, invest in companion diagnostic development early in the therapeutic lifecycle to ensure that biomarker-defined patient populations are identified and validated for regulatory submissions. Second, build flexible manufacturing and supply chain arrangements to mitigate disruptions and optimize cost structures for imaging equipment, specialized reagents, and cell therapy inputs. Third, pursue collaborative clinical models that engage multi-stakeholder consortia-including academic centers, community hospitals, and patient advocacy groups-to accelerate enrollment and broaden the evidentiary base for diverse patient populations.
Additionally, companies should adopt data-centric strategies that leverage real-world evidence and AI-enabled analytics to demonstrate value to payers and clinicians. This entails designing post-market evidence generation plans that align with health system priorities and developing interfaces that integrate diagnostic outputs into electronic health records and clinical decision support tools. Finally, prioritize ethical deployment and patient-centric communication, especially for novel modalities with complex risk profiles, to foster clinician trust, support shared decision-making, and enhance long-term adoption.
A rigorous mixed-methods research approach combining literature synthesis, expert stakeholder engagement, and cross-validated primary insights to ensure actionable conclusions
The research methodology underpinning this report combines systematic literature synthesis, expert interviews, and cross-validated primary research to ensure a rigorous and current evidence base. Peer-reviewed publications, clinical trial registries, regulatory filings, and technical standards informed the technical and clinical background, while qualitative interviews with clinicians, industry executives, and payers provided contextual insights into operational challenges and adoption drivers. Secondary sources were triangulated with primary insights to validate assumptions and identify emerging inflection points.
Quantitative inputs were subjected to sensitivity analyses and scenario testing to assess the robustness of thematic conclusions, and a tiered evidence assessment framework guided the weighting of data sources. Special attention was paid to translational evidence linking diagnostic performance to clinical outcomes, the regulatory landscape for companion diagnostics and advanced therapies, and operational considerations for imaging and surgical deployment. This mixed-methods approach supports a pragmatic and actionable set of findings tailored to industry and clinical stakeholders.
Concluding synthesis highlighting the necessity of integrated diagnostics, translational investment, and stakeholder alignment to realize durable clinical benefits in brain tumor care
In sum, the trajectory of brain tumor diagnosis and therapeutics will be defined by the interplay of molecularly informed diagnostics, targeted and immunologic therapeutic strategies, and operational pathways that translate clinical promise into broad patient benefit. Cross-disciplinary collaboration remains essential to overcome persistent scientific and logistical barriers, particularly in the realms of drug delivery to the central nervous system, biomarker validation, and long-term safety monitoring for novel modalities. Equally important is the alignment of evidence generation with payer expectations to ensure that breakthroughs become accessible treatments rather than isolated clinical successes.
Moving forward, stakeholders that integrate robust diagnostic strategies, flexible commercial planning, and patient-centered communication will be best positioned to convert innovation into improved outcomes. Continued investment in translational research, coupled with pragmatic deployment strategies and regional sensitivity, will determine which technologies and therapies achieve durable clinical integration.
Please Note: PDF & Excel + Online Access - 1 Year
Table of Contents
185 Pages
- 1. Preface
- 1.1. Objectives of the Study
- 1.2. Market Segmentation & Coverage
- 1.3. Years Considered for the Study
- 1.4. Currency
- 1.5. Language
- 1.6. Stakeholders
- 2. Research Methodology
- 3. Executive Summary
- 4. Market Overview
- 5. Market Insights
- 5.1. Adoption of AI-driven radiomics platforms for personalized glioblastoma treatment planning
- 5.2. Emergence of blood-based liquid biopsy assays for noninvasive detection and monitoring of tumor recurrence
- 5.3. Implementation of intraoperative fluorescence-guided surgery techniques to enhance tumor margin resection
- 5.4. Rapid growth of CAR T-cell therapies engineered to target glioma-specific antigens with improved penetration
- 5.5. Expansion of molecular imaging agents enabling real-time assessment of tumor metabolism and therapeutic response
- 5.6. Development of implantable drug delivery systems for localized and sustained release of chemotherapeutics in brain tumors
- 5.7. Commercialization of portable high-field MRI devices for point-of-care neuro-oncology diagnostics in community settings
- 6. Cumulative Impact of United States Tariffs 2025
- 7. Cumulative Impact of Artificial Intelligence 2025
- 8. Brain Tumor Diagnosis & Therapeutics Market, by Therapeutic Modality
- 8.1. Chemotherapy
- 8.1.1. Alkylating Agents
- 8.1.2. Antimetabolites
- 8.1.3. Platinum Compounds
- 8.2. Immunotherapy
- 8.2.1. CAR T-Cell Therapy
- 8.2.2. Checkpoint Inhibitors
- 8.2.3. Vaccine Therapy
- 8.3. Radiation Therapy
- 8.4. Surgery
- 8.5. Targeted Therapy
- 8.5.1. Antiangiogenic Agents
- 8.5.2. MTOR Inhibitors
- 8.5.3. Tyrosine Kinase Inhibitors
- 9. Brain Tumor Diagnosis & Therapeutics Market, by Imaging Technology
- 9.1. Computed Tomography
- 9.2. Magnetic Resonance Imaging
- 9.2.1. Diffusion Tensor Imaging
- 9.2.2. Functional MRI
- 9.2.3. Spectroscopy
- 9.3. Molecular Diagnostics
- 9.4. Positron Emission Tomography
- 9.4.1. Amino Acid Tracers
- 9.4.2. FDG
- 9.5. Ultrasound
- 10. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Type
- 10.1. Acoustic Neuroma
- 10.2. Glioma
- 10.3. Meningioma
- 10.4. Pituitary Tumor
- 11. Brain Tumor Diagnosis & Therapeutics Market, by Tumor Grade
- 11.1. High Grade
- 11.2. Low Grade
- 12. Brain Tumor Diagnosis & Therapeutics Market, by Patient Age Group
- 12.1. Adult
- 12.2. Geriatric
- 12.3. Pediatric
- 13. Brain Tumor Diagnosis & Therapeutics Market, by End User
- 13.1. Ambulatory Surgical Centers
- 13.2. Diagnostic Laboratories
- 13.3. Hospitals
- 13.4. Research Institutes
- 14. Brain Tumor Diagnosis & Therapeutics Market, by Region
- 14.1. Americas
- 14.1.1. North America
- 14.1.2. Latin America
- 14.2. Europe, Middle East & Africa
- 14.2.1. Europe
- 14.2.2. Middle East
- 14.2.3. Africa
- 14.3. Asia-Pacific
- 15. Brain Tumor Diagnosis & Therapeutics Market, by Group
- 15.1. ASEAN
- 15.2. GCC
- 15.3. European Union
- 15.4. BRICS
- 15.5. G7
- 15.6. NATO
- 16. Brain Tumor Diagnosis & Therapeutics Market, by Country
- 16.1. United States
- 16.2. Canada
- 16.3. Mexico
- 16.4. Brazil
- 16.5. United Kingdom
- 16.6. Germany
- 16.7. France
- 16.8. Russia
- 16.9. Italy
- 16.10. Spain
- 16.11. China
- 16.12. India
- 16.13. Japan
- 16.14. Australia
- 16.15. South Korea
- 17. Competitive Landscape
- 17.1. Market Share Analysis, 2024
- 17.2. FPNV Positioning Matrix, 2024
- 17.3. Competitive Analysis
- 17.3.1. F. Hoffmann-La Roche Ltd
- 17.3.2. Novartis AG
- 17.3.3. Pfizer Inc.
- 17.3.4. Merck & Co., Inc.
- 17.3.5. Bristol Myers Squibb Company
- 17.3.6. Johnson & Johnson
- 17.3.7. AbbVie Inc.
- 17.3.8. Amgen Inc.
- 17.3.9. Bayer AG
- 17.3.10. Eli Lilly and Company
- 17.3.11. GlaxoSmithKline plc
- 17.3.12. Sanofi S.A.
- 17.3.13. Takeda Pharmaceutical Company Limited
- 17.3.14. AstraZeneca PLC
- 17.3.15. Agios Pharmaceuticals, Inc.
- 17.3.16. Ipsen Pharma
- 17.3.17. Karyopharm Therapeutics Inc.
- 17.3.18. Mundipharma International Limited
- 17.3.19. Novocure GmbH
- 17.3.20. VBL Therapeutics
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
